I see that MYGN already published 3 peer-reviewed papers on Prolaris test with the Lancet oncology being the first in 2011. Full data from the Duke university study I linked to in #msg-87805550 should be published soon (has been accepted). As for GHDX, didn't see any peer-reviewed paper just the PR and Abstract no 2131 at AUA 2013 with no detailed data. So, at this point it is impossible to know which test is a better outcome predictor for prostate cancer patients.
Market Data 
Markets 
AI
